Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.370
+0.060 (1.39%)
At close: Apr 2, 2026, 4:00 PM EDT
4.450
+0.080 (1.83%)
After-hours: Apr 2, 2026, 7:49 PM EDT

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,2551,568355331143448
Market Cap Growth
234.63%342.19%7.14%131.66%-68.13%-55.28%
Enterprise Value
1,0061,316276.37245.99113.38362.21
Last Close Price
4.375.501.731.772.2611.65
PE Ratio
--16.18-4.81-1.84-0.60-2.51
PS Ratio
128.45160.4242.5521.4257.09-
PB Ratio
5.046.354.964.42150.534.70
P/TBV Ratio
5.657.126.052.74104.674.60
P/FCF Ratio
--16.71-4.35-4.30-1.31-3.39
P/OCF Ratio
--16.84-4.37-4.53-1.62-3.83
EV/Sales Ratio
102.91134.6433.1715.9245.31-
EV/EBITDA Ratio
--12.03-3.06-3.46-0.70-2.10
EV/EBIT Ratio
--11.91-3.02-3.40-0.70-2.09
EV/FCF Ratio
--14.02-3.39-3.20-1.04-2.74
Debt / Equity Ratio
0.280.280.860.7961.550.66
Debt / EBITDA Ratio
-0.62-0.62-0.68-0.84-0.36-0.36
Debt / FCF Ratio
-0.73-0.73-0.75-0.77-0.54-0.48
Net Debt / Equity Ratio
-1.02-1.02-1.09-1.13-31.06-0.90
Net Debt / EBITDA Ratio
2.302.300.871.200.180.50
Net Debt / FCF Ratio
2.692.690.961.110.270.65
Asset Turnover
0.040.040.050.100.010
Quick Ratio
12.0612.065.323.931.402.88
Current Ratio
12.2312.235.424.081.543.08
Return on Equity (ROE)
-68.45%-68.45%-121.94%-294.04%-344.67%-100.68%
Return on Assets (ROA)
-43.88%-43.88%-54.91%-48.45%-95.49%-73.29%
Return on Invested Capital (ROIC)
-22619.86%-22619.86%-1295.73%-768.38%-1458.89%-2546.92%
Return on Capital Employed (ROCE)
-49.01%-49.01%-67.72%-72.63%-143.95%-83.71%
Earnings Yield
-8.68%-6.18%-20.81%-54.24%-167.26%-39.83%
FCF Yield
-7.47%-5.98%-23.01%-23.23%-76.31%-29.53%
Buyback Yield / Dilution
-27.82%-27.82%-115.41%-164.20%-16.74%-113.13%
Total Shareholder Return
-27.82%-27.82%-115.41%-164.20%-16.74%-113.13%
Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q